Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREATE phase II trial of crizotinib in ALK- or MET-driven advanced rare tumors
NL-OMON55860Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of crizotinib in anaplastic large cell lymphoma (ALCL), inflammatory pseudotumor (IPT), papillary renal cell carcinoma (PRCC) and 3 more (12 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Antitumor activity and Safety. Started Apr 2013; status: active, not recruiting.
02
Drugs
crizotinib
03
Conditions
anaplastic large cell lymphoma (ALCL)inflammatory pseudotumor (IPT)papillary renal cell carcinoma (PRCC)alveolar soft part sarcoma (ASPS)clear cell sarcoma (CCS)
Beyond the preview
Go deeper on NL-OMON55860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55860.